Paper-Based Sensor Detects Alzheimer’s and Parkinson’s Biomarkers in One Test

Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are among the most daunting diagnostic challenges in modern medicine. By the time symptoms appear, the pathological processes driving these conditions have often been at work for years or even decades, and the tools currently available for confirming a diagnosis—cerebrospinal fluid analysis and brain imaging—are invasive, costly, and poorly suited to the clinics and communities where early detection would matter most. A research team at Jamia Hamdard in New Delhi now reports a device that could change that calculus: a disposable, paper-based electrochemical sensor capable of detecting molecular signatures of both Alzheimer’s and Parkinson’s disease simultaneously, from a single small sample, in a format cheap enough for widespread point-of-care use.

The study, published in Biomedical Microdevices, describes a multiplexed aptasensor built on a humble cellulose substrate. Led by Jagriti Narang, with Saumitra Singh, Anam Ayaz, Osheen Ansari, and Humaira Farooqi as co-authors, the team inscribed carbon and silver electrodes directly onto paper using screen-printing techniques, creating a flexible, lightweight sensing platform that requires no expensive laboratory infrastructure to manufacture. The device features two independently functionalized working electrodes, each dedicated to a different disease biomarker, allowing a single measurement session to interrogate both Alzheimer’s-associated and Parkinson’s-associated proteins at once.

The two targets at the heart of the sensor are amyloid beta-42, the peptide fragment notorious for aggregating into the plaques that define Alzheimer’s disease, and alpha synuclein-60, a protein species linked to the Lewy body pathology characteristic of Parkinson’s disease. Both molecules circulate at vanishingly low concentrations in biological fluids, which is precisely why conventional diagnostic approaches struggle. Detecting them reliably demands a sensing interface that can amplify vanishingly small molecular events into measurable signals—something the Indian team achieved through a clever combination of nanomaterials and biological recognition elements.

The amplification strategy centers on zinc oxide nanorods, which the researchers grew onto the carbon working electrodes to dramatically increase the effective surface area available for biomolecule immobilization. Zinc oxide is a favorite material in biosensor engineering for good reason: it is biocompatible, electrically conductive, and its high isoelectric point makes it an excellent scaffold for anchoring proteins and nucleic acids. By decorating the nanorod-covered electrodes with target-specific DNA aptamers—short, synthetic single-stranded DNA sequences that fold into precise three-dimensional shapes capable of binding a single molecular target with antibody-like specificity—the team created two distinct biorecognition surfaces on one chip.

The readout method is electrochemical impedance spectroscopy, a label-free technique that measures how much a surface resists the transfer of electrons in solution. In the sensor’s baseline state, a small redox probe can shuttle freely between the electrode and the surrounding electrolyte. When the target protein—amyloid beta-42 on one electrode, alpha synuclein-60 on the other—binds to its aptamer, the bulky protein layer physically blocks that electron transfer, increasing what electrochemists call the charge-transfer resistance. The magnitude of that increase scales with the concentration of the target, so a simple impedance measurement translates directly into a quantitative biomarker reading, with no chemical labels, enzymes, or secondary reagents required.

The performance figures are striking for a paper-based platform. The sensor exhibited a linear response spanning five orders of magnitude, from 0.1 nanograms per milliliter up to 10 micrograms per milliliter, for both biomarkers. The limits of detection came out at 4.41 nanograms per milliliter for amyloid beta-42 and 2.62 nanograms per milliliter for alpha synuclein-60—concentrations low enough to be relevant for physiological monitoring. Equally important, the team demonstrated that the device retains its responsiveness in artificial cerebrospinal fluid and artificial saliva, two physiologically mimicked matrices that are far messier than a clean buffer solution. Saliva, in particular, is an attractive sample type for decentralized testing because it can be collected non-invasively by patients themselves, without needles or clinical staff.

Multiplexing is the quiet innovation here. Most existing biosensors detect a single biomarker, but neurodegenerative diseases do not present as single-molecule problems. Alzheimer’s and Parkinson’s share overlapping symptoms, overlapping pathologies, and in many patients overlapping diagnoses, and clinicians increasingly recognize that distinguishing between them—or catching both—requires looking at multiple molecular indicators in parallel. By building two independently addressable working electrodes onto one paper strip, the researchers created a platform where a single drop of sample could, in principle, yield a two-disease molecular profile simultaneously, at a fraction of the cost of running separate assays.

The broader context makes the work timely. Paper-based microfluidics and screen-printed electrodes have surged in popularity over the past decade because they promise something the diagnostics industry has long struggled to deliver: laboratory-quality molecular testing at a price point and form factor suitable for clinics in resource-limited settings, pharmacies, and eventually the home. The COVID-19 pandemic demonstrated both the demand for and the feasibility of rapid, disposable biosensing, and researchers worldwide have been racing to apply the same design philosophy to chronic diseases, where early detection could shift the entire trajectory of patient care. Electrochemical aptasensors, which pair the stability and synthetic ease of DNA with the sensitivity of electrochemical transduction, have emerged as one of the most promising routes.

The authors are candid about the distance between proof of concept and clinical deployment. Their abstract explicitly flags the hurdles that remain: the low concentrations of neurodegenerative biomarkers in real samples, interference from the complex protein mixtures in genuine biological fluids, nonspecific adsorption of off-target molecules onto the sensor surface, variability from sensor to sensor, and questions of long-term storage stability. The current results were obtained in artificial matrices rather than real patient samples, and the team acknowledges that optimization of surface immobilization chemistry, antifouling behavior, and sensitivity—followed by validation using real clinical saliva and cerebrospinal fluid—will be required before the platform can approach practical diagnostic use.

Those caveats are standard for early-stage biosensor research, and they do not diminish the significance of what has been demonstrated. What the Jamia Hamdard team has built is a complete architectural template: a disposable paper substrate, printed carbon and silver electrodes, nanostructured signal amplification, aptamer-based molecular recognition, and label-free impedance readout, all integrated into a multiplexed format targeting two of the most consequential proteins in neurodegeneration. If subsequent studies can carry that architecture through clinical validation, the vision of a cheap paper strip that screens for Alzheimer’s and Parkinson’s in a doctor’s office—or even at home—moves a meaningful step closer to reality, and the growing global burden of these diseases gains a potential new line of early defense.

Subject of Research: A multiplexed paper-based impedimetric aptasensor using zinc oxide nanorods for simultaneous detection of Alzheimer's and Parkinson's disease biomarkers

Article Title: Multiplexed impedimetric zinc oxide nanorods-modified aptasensor on carbon ink-inscribed paper electrodes for the specific and sensitive co-detection of Alzheimer’s and Parkinson’s disease

Article References: Multiplexed impedimetric zinc oxide nanorods-modified aptasensor on carbon ink-inscribed paper electrodes for the specific and sensitive co-detection of Alzheimer’s and Parkinson’s disease. (n.d.). https://doi.org/10.1007/s10544-026-00855-5

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00855-5

Keywords: Alzheimer's disease, Parkinson's disease, biosensor, aptasensor, zinc oxide nanorods, electrochemical impedance spectroscopy, amyloid beta-42, alpha synuclein, paper-based diagnostics, point-of-care testing, multiplexed sensing, neurodegenerative diseases